Paratek gets FDA green light for two drugs
Paratek Pharmaceuticals has received the FDA’s blessing for Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia, or CABP, and acute skin and skin structure infections, or ABSSSI.
The product, a modernized tetracycline, is a once-daily IV and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and drug-resistant strains.
“In the face of ever-increasing antibiotic resistance, the FDA approved Nuzyra with a label having full approval for both CABP and ABSSSI. We are excited to bring to physicians an effective, well tolerated monotherapy option for patients,” Paratek president, COO, and chief medical officer Evan Loh said in a statement. “Nuzyra offers clinicians the ability to treat patients with the IV and transition them home to complete treatment with the oral formulation. This potentially helps reduce hospitalizations and the costs associated with hospital stays.”
“The approval of NUZYRA is an historic milestone for Paratek as it represents 20 years of research and development of this life-saving antibiotic for patients affected by community-acquired infections,” Paratek chairman and CEO Michael Bigham said in a statement.”There are countless champions of Nuzyra who have been tireless in their efforts to ensure its advancement to commercialization — from patients, clinicians and study investigators to our Paratek team. We are grateful to all who played a role in making NUZYRA available to patients in need. We are excited to launch Nuzyra early next year.”
In a separate development, Paratek also received the FDA’s nod for Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of old and older.
The product is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate-to-severe acne in the community setting.
Paratek has exclusively licensed U.S. development and commercialization rights of Seysara for the treatment of acne to Allergan, who has assigned such rights to Almirall SA. Paratek retains development and commercialization rights in the rest of the world.
FDA green lights Insmed’s Arikayce for lung disease
The Food and Drug Administration has cleared Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex, or MAC, in a limited population of patients with the disease who do not respond to conventional treatment.
MAC is a type of nontuberculous mycobacteria commonly found in water and soil. Symptoms of disease in patients with MAC include persistent cough, fatigue, weight loss, night sweats, and occasionally shortness of breath and coughing up of blood.
“As bacteria continue to grow impervious to currently available antibiotics, we need to encourage the development of drugs that can treat resistant infections. That means utilizing novel tools intended to streamline development and encourage investment into these important endeavors,” FDA commissioner Scott Gottlieb said.
“This approval is the first time a drug is being approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, and it marks an important policy milestone,” Gottlieb said. “This pathway, advanced by Congress, aims to spur development of drugs targeting infections that lack effective therapies. We’re seeing a lot of early interest among sponsors in using this new pathway, and it’s our hope that it’ll spur more development and approval of antibacterial drugs for treating serious or life-threatening infections in limited populations of patients with unmet medical needs.”
FDA kicks off new efforts to advance complex generics
FDA commissioner Scott Gottlieb on Tuesday announced a series of guidance documents that will advance the development of generic transdermal and topical delivery systems.
“The increased transparency and predictability provided by these and other product-specific recommendations gives applicants seeking to develop generic copies of these complex products a better opportunity to efficiently advance these products and prepare better and more complete submissions,” Gottlieb said, in a statement.
TDS products are applied to a patient’s skin and deliver the drug into and through the skin. These products should deliver the correct medication dose consistently and for the expected length of time. They should adhere consistently and uniformly to the skin, and should withstand variables such as exposure to water, humidity and movement. Because of the inherent complexity of delivering a drug through a TDS, making generic copies of these complex drugs can be especially hard. As a result, many branded TDS products like drug patches have not faced timely generic competition.
“The new guidances we’re releasing include the revised draft guidance, Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs, which provides updated advice for the design and conduct of studies evaluating the adhesive performance of a proposed generic TDS. A second draft guidance, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs, provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation and sensitization potential of a proposed generic TDS,” Gottlieb said.
In addition to these documents, the FDA also is issuing 25 product-specific guidance documents. These include two new and 23 revised guidances. These documents will support industry in identifying appropriate science-based methodologies and evidence for developing generic TDS products.
“In too many cases, there is no generic competition for these costly branded drugs even after they have lost their exclusivity protections. We have made a new commitment to develop product-specific guidance documents laying out how to develop a generic copy of a branded medicine for any currently marketed, branded complex medicine in an effort to advance a more efficient and effective framework for developing generic copies of complex drugs. We will strive to release each document as soon as scientific recommendations can be developed,” Gottlieb said.
Gottlieb said that complex drugs involve cases where the drug is often harder to formulate and manufacture because it has a complex formulation or complex active ingredient. In other cases, the drug acts locally on the tissue rather than through the concentration in the blood. This includes inhaled drugs that act directly on the lungs, a topical patch that acts directly on the skin, or an eye drop that acts on the surface of the eye. The therapeutic effect of these types of drugs does not necessarily correlate with the amount in the blood and can be more difficult to measure through the blood. They can raise other issues that make the traditional, and often simpler, metrics generally used to evaluate generic drugs and prove sameness difficult to employ. There’s often no easy way to make the demonstrations necessary for generic approval.
In the coming months, the FDA said it would advance other new policies to promote more generic competition for these complex drugs. This includes the development of new analytical tools and in vitro tests that may be more accurate and sensitive, and reproducible tools to demonstrating sameness between a generic and branded version of complex drugs. More efficient tools for demonstrating sameness can reduce product development time and cost and inform regulatory decisions, Gottlieb said.
The FDA also will be issuing an umbrella guidance to help generic drug developers address some of the most challenging regulatory and scientific issues encountered when they try to make generic copies of complex drugs. This umbrella guidance will be followed by a series of more targeted guidances to help address legal questions that may be blocking generic competition.
Gottlieb said the agency also will be clarifying the agency’s policies on how it evaluates potential differences in instructions for using complex generic drugs, for example when there are directions for how to use a specific drug delivery device in an approved drug-device combination.